logo
RCAT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Red Cat Holdings, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

RCAT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Red Cat Holdings, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

NEW YORK, May 29, 2025 /PRNewswire/ — Attorney Advertising — Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Red Cat Holdings, Inc. ('Red Cat' or 'the Company') (NASDAQ: RCAT) and certain of its officers.
Class Definition
This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Red Cat securities between March 18, 2022 and January 15, 2025, both dates inclusive (the 'Class Period'). Such investors are encouraged to join this case by visiting the firm's site: bgandg.com/RCAT.
Case Details
The complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and prospects. Specifically, the Complaint alleges that Defendants made false and/or misleading statements and/or failed to disclose that: (1) the Salt Lake City Facility's production capacity, and Defendants' progress in developing the same, was overstated; (2) the overall value of the SRR Contract was overstated; and (3) as a result, Defendants' public statements were materially false and misleading at all relevant times.
What's Next?
A class action lawsuit has already been filed. If you wish to review a copy of the Complaint, you can visit the firm's site: bgandg.com/RCAT. or you may contact Peretz Bronstein, Esq. or his Client Relations Manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC at 332-239-2660. If you suffered a loss in Red Cat you have until July 22, 2025, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as lead plaintiff.
There is No Cost to You
We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.
Why Bronstein, Gewirtz & Grossman
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
Follow us for updates on LinkedIn, X, Facebook, or Instagram.
Attorney advertising. Prior results do not guarantee similar outcomes.
Contact
Bronstein, Gewirtz & Grossman, LLCPeretz Bronstein or Nathan Miller332-239-2660 | info@bgandg.com
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

IceCure's ProSense® Featured at Japanese Breast Cancer Society Conference: Updated Positive Clinical Data Shows 99% Recurrence Free Rate with Cryoablation
IceCure's ProSense® Featured at Japanese Breast Cancer Society Conference: Updated Positive Clinical Data Shows 99% Recurrence Free Rate with Cryoablation

Malaysian Reserve

time4 hours ago

  • Malaysian Reserve

IceCure's ProSense® Featured at Japanese Breast Cancer Society Conference: Updated Positive Clinical Data Shows 99% Recurrence Free Rate with Cryoablation

Breast surgeon, Professor Eisuke Fukuma, a highly regarded cryoablation expert & ProSense® user at Kameda Medical Center, presented updated breast cancer cryoablation data from an independent study of over 600 women from 2006 to 2023 Independent ProSense® study by Professor Hisanori Kawamoto demonstrating 0% breast cancer local recurrence wins Best of Breast Cancer Award Leading US Breast Surgeon, Dr. Richard Fine, presented data from IceCure's ICE3 study & discussed other recent publications on breast cancer cryoablation CAESAREA, Israel, July 25, 2025 /PRNewswire/ — IceCure Medical Ltd. (Nasdaq: ICCM) ('IceCure', 'IceCure Medical' or the 'Company'), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced its participation in the 33rd Annual Meeting of the Japanese Breast Cancer Society's Conference (the 'Conference') which took place earlier this month in Tokyo. 'We believe ProSense® can make a significant impact on improving breast cancer outcomes in Japan by providing women with a minimally invasive option. This year's Conference was highly productive as we engaged with breast surgeons, thought leaders, and industry participants,' stated Eyal Shamir, IceCure's Chief Executive Officer. 'Working with Terumo Corporation in Japan, the country's largest medical device company, we anticipate strong commercial adoption upon regulatory approval for breast cancer, especially given the strong data coming from independent Japanese studies.' IceCure, a sponsor of the Conference, hosted a cryoablation-focused luncheon on Friday, July 11, 2025, led by Professor Takayuki Kinoshita, Division of Breast Surgery, NHO Tokyo Medical Center, with presentations made by: Professor Eisuke Fukuma, who has performed over 600 breast cryoablation procedures, the majority of which were conducted with ProSense®, presented the latest data from his ongoing activity to treat breast cancer at Kameda Medical Center. Professor Fukuma's presentation included the following: From June 2006 through December 2023, 535 breast cancer patients with tumor lesions of less than 15 millimeters and 76 patients with tumor lesions of less than 10 millimeters were treated. The overall ipsilateral breast tumor recurrence rate (IBTR') was 0.98% for up to 17 years, resulting in a 99.02% recurrence free rate. For a subpopulation with more than 10 years follow up, including 51 patients with invasive ductal carcinoma and 20 patients with ductal carcinoma in situ, the IBTR was 2.8%, resulting in a 97.2% recurrence free rate. From June 2006 through December 2023, 535 breast cancer patients with tumor lesions of less than 15 millimeters and 76 patients with tumor lesions of less than 10 millimeters were treated. The overall ipsilateral breast tumor recurrence rate (IBTR') was 0.98% for up to 17 years, resulting in a 99.02% recurrence free rate. For a subpopulation with more than 10 years follow up, including 51 patients with invasive ductal carcinoma and 20 patients with ductal carcinoma in situ, the IBTR was 2.8%, resulting in a 97.2% recurrence free rate. Dr. Richard Fine of West Cancer Center & Research Institute in the U.S., and a clinical investigator of IceCure's successfully completed ICE3 breast cancer clinical study, presented findings from the ICE3 study as well as data from independent studies of ProSense® in breast cancer. The Conference gave the Best of Breast Cancer award to an independent study published in the journal Breast Cancer titled 'Percutaneous ultrasound–guided cryoablation for early–stage primary breast cancer: a follow–up study in Japan'. This study was led by Professor Hisanori Kawamoto, M.D., Ph.D. from the Department of Breast Surgery, Breast and Imaging Center at St. Marianna University School of Medicine in Japan and reported zero (0%) breast cancer local recurrence 5 years following treatment with ProSense®. Dr. Kawamoto commented, 'This is a very important study in Japan, where we are experiencing an upward trend in breast cancer cases, especially among women in their late 40s to their early 60s. These are women who often are at very active stages of their life and therefore there is a growing demand for treatment options that minimize the chance of, or even avoid, hospitalization, in addition to resulting in favorable clinical and cosmetic outcomes. We are very pleased with these results and are hopeful that ProSense® may become a favored option in Japan upon regulatory approval for early-stage breast cancer.' Terumo Corporation is expected to submit an application to the Pharmaceuticals and Medical Devices Agency ('PMDA') of Japan for regulatory clearance for breast cancer indication for the ProSense® system by the end of 2025. About ProSense®The ProSense® Cryoablation System provides a minimally invasive treatment option to destroy tumors by freezing them. The system uniquely harnesses the power of liquid nitrogen to create large lethal zones for maximum efficacy in tumor destruction in benign and cancerous lesions, including breast, kidney, lung, and liver. ProSense® enhances patient and provider value by accelerating recovery, reducing pain, surgical risks, and complications. With its easy, transportable design and liquid nitrogen utilization, ProSense® opens that door to fast and convenient office-based procedures for breast tumors. About IceCure MedicalIceCure Medical (Nasdaq: ICCM) develops and markets advanced liquid-nitrogen-based cryoablation therapy systems for the destruction of tumors (benign and cancerous) by freezing, with the primary focus areas being breast, kidney, bone and lung cancer. Its minimally invasive technology is a safe and effective alternative to hospital surgical tumor removal that is easily performed in a relatively short procedure. The Company's flagship ProSense® system is marketed and sold worldwide for the indications cleared and approved to date including in the U.S., Europe and Asia. Forward Looking StatementsThis press release contains forward-looking statements within the meaning of the 'safe harbor' provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Words such as 'expects,' 'anticipates,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates' and similar expressions or variations of such words are intended to identify forward-looking statements. For example, IceCure is using forward looking statements in this press release when it discusses: the belief that ProSense® can make a significant impact on improving breast cancer outcomes in Japan; the Company's anticipation of strong commercial adoption upon regulatory approval of ProSense® for breast cancer; the belief of the importance of 'Percutaneous ultrasound–guided cryoablation for early–stage primary breast cancer: a follow–up study in Japan;' and that Terumo Corporation is expected to submit a PMDA application for regulatory clearance for breast cancer indication for the ProSense® system by the end of 2025. Historical results of scientific research and clinical and preclinical trials do not guarantee that the conclusions of future research or trials will suggest identical or even similar conclusions. Important factors that could cause actual results, developments and business decisions to differ materially from those anticipated in these forward-looking statements include, among others: the Company's planned level of revenues and capital expenditures; the Company's available cash and its ability to obtain additional funding; the Company's ability to market and sell its products; legal and regulatory developments in the United States and other countries; the Company's ability to maintain its relationships with suppliers, distributors and other partners; the Company's ability to maintain or protect the validity of its patents and other intellectual property; the Company's ability to expose and educate medical professionals about its products; political, economic and military instability in the Middle East, specifically in Israel; as well as those factors set forth in the Risk Factors section of the Company's Annual Report on Form 20-F for the year ended December 31, 2024 filed with the SEC on March 27, 2025, and other documents filed with or furnished to the SEC which are available on the SEC's website, The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law. References and links to websites have been provided in this press release as a convenience, and the information contained on such websites is not incorporated by reference herein. IR Contact: Email: investors@ Michael Polyviou Phone: 732-232-6914 Logo – View original content:

S&P 500 and Nasdaq close at records
S&P 500 and Nasdaq close at records

The Star

time9 hours ago

  • The Star

S&P 500 and Nasdaq close at records

The S&P 500 climbed 0.40% to end the session at 6,388.64 points. The Nasdaq gained 0.24% to 21,108.32 points, while the Dow rose 0.47% to 44,901.92 points. NEW YORK: The S&P 500 and Nasdaq notched record high closes on Friday, lifted by optimism the US could soon reach a trade deal with the European Union, while Deckers Outdoor surged following a strong quarter for the maker of UGG boots and Hoka sneakers. European Commission President Ursula von der Leyen will meet US President Donald Trump on Sunday in Scotland after EU officials and diplomats said they expected to reach a framework trade deal this weekend. Trump said earlier that the odds of a US-EU trade deal were "50-50".

URGENT: The M&A Class Action Firm Launches Legal Inquiry for the Merger
URGENT: The M&A Class Action Firm Launches Legal Inquiry for the Merger

Malaysian Reserve

time10 hours ago

  • Malaysian Reserve

URGENT: The M&A Class Action Firm Launches Legal Inquiry for the Merger

NEW YORK, July 25, 2025 /PRNewswire/ — Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the 'M&A Class Action Firm'), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating CARGO Therapeutics, Inc. (NASDAQ: CRGX) related to its sale to Concentra Biosciences, LLC for $4.379 in cash per CARGO share, plus one non-transferable contingent value right, representing the right to receive: (i) 100% of the closing net cash of CARGO in excess of $217.5 million; and (ii) 80% of the net proceeds from the sale, license, or other disposition of either (a) CRG-022, a CDRR CAR T-cell therapy, or (b) CRG-023, a CD19/CD20/CD22 tri-specific CAR T therapy, or (c) the Allogeneic Platform, that occurs within 2 years following the closing. Click here for more information It is free and there is no cost or obligation to you. Hudson Global, Inc. (HSON) related to its merger with Star Equity Holdings, Inc. Upon completion of the proposed transaction, Hudson shareholders will own approximately 79% of the combined company. ACT NOW. The Shareholder Vote is scheduled for August 21, 2025. Click here for more information It is free and there is no cost or obligation to you. Breeze Holdings Acquisition Corp. (OTC: BRZH), relating to its proposed merger with YD Biopharma Limited. Under the terms of the agreement, all Breeze Holdings ordinary shares will be converted into the right to receive one ordinary share of the surviving company. ACT NOW. The Shareholder Vote is scheduled for August 14, 2025. Click here for more information It is free and there is no cost or obligation to you. Enzo Biochem, Inc. (OTCMKTS: ENZB) related to its sale to Battery Ventures for $0.70 per share in cash without interest to Enzo shareholders. ACT NOW. The Shareholder Vote is scheduled for August 19, 2025. Click here for more information It is free and there is no cost or obligation to you. NOT ALL LAW FIRMS ARE THE SAME. Before you hire a law firm, you should talk to a lawyer and ask: Do you file class actions and go to Court? When was the last time you recovered money for shareholders? What cases did you recover money in and how much? About Monteverde & Associates PC Our firm litigates and has recovered money for shareholders…and we do it from our offices in the Empire State Building. We are a national class action securities firm with a successful track record in trial and appellate courts, including the U.S. Supreme Court. No company, director or officer is above the law. If you own common stock in the above listed company and have concerns or wish to obtain additional information free of charge, please visit our website or contact Juan Monteverde, Esq. either via e-mail at jmonteverde@ or by telephone at (212) 971-1341. Contact:Juan Monteverde, & ASSOCIATES PCThe Empire State Building350 Fifth Ave. Suite 4740New York, NY 10118United States of Americajmonteverde@ (212) 971-1341 Attorney Advertising. (C) 2025 Monteverde & Associates PC. The law firm responsible for this advertisement is Monteverde & Associates PC ( Prior results do not guarantee a similar outcome with respect to any future matter.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store